The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Consulting or Advisory Role - AstraZeneca; Merck Sharp & Dohme; Roche
AdvanTIG-206: Anti-TIGIT monoclonal antibody (mAb) ociperlimab (BGB-A1217; OCI) plus anti-programmed cell death protein-1 (PD-1) mAb tislelizumab (TIS) plus BAT1706 versus TIS plus BAT1706 as first-line (1L) treatment for advanced hepatocellular carcinoma (HCC).
 
Jia Fan
No Relationships to Disclose
 
Zhenggang Ren
No Relationships to Disclose
 
Chiun Hsu
Honoraria - AstraZeneca; Bayer; Bristol-Myers Squibb/Ono Pharmaceutical; Eisai; Ipsen; MSD; Novartis; PharmaEngine; Roche; TTY Biopharm
Research Funding - Bristol-Myers Squibb/Ono Pharmaceutical; Ipsen; Roche
 
Yabing Guo
No Relationships to Disclose
 
Tianqiang Song
No Relationships to Disclose
 
Wentao Wang
No Relationships to Disclose
 
Yee Chao
No Relationships to Disclose
 
Yujuan Gao
Employment - BeiGene
Stock and Other Ownership Interests - BeiGene
Travel, Accommodations, Expenses - BeiGene
 
Vincent Li
Employment - BeiGene
Stock and Other Ownership Interests - BeiGene
 
Salvatore Ferro
Employment - BeiGene
Stock and Other Ownership Interests - AstraZeneca; BeiGene
 
Chia-Jui Yen
No Relationships to Disclose